These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 35037948)

  • 21. Physicians' Attitudes Toward Prescribable mHealth Apps and Implications for Adoption in Germany: Mixed Methods Study.
    Dahlhausen F; Zinner M; Bieske L; Ehlers JP; Boehme P; Fehring L
    JMIR Mhealth Uhealth; 2021 Nov; 9(11):e33012. PubMed ID: 34817385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Practical use of digital health applications (DiGA) in internal medicine].
    Mittermaier M; Sina C; Richter JG; Raspe M; Stais P; Vehreschild J; Wolfrum S; Anthes C; Möckel M;
    Internist (Berl); 2022 Mar; 63(3):245-254. PubMed ID: 35037948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The new approval process for the reimbursement of digital health applications (DiGA) from the perspective of the German statutory health insurance].
    Gregor-Haack J; Busse T; Hagenmeyer EG
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1220-1227. PubMed ID: 34459939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experiences of digital health care applications (DIGA) manufacturers with the BfArM Fast-Track procedure].
    Heimann P; Lorenz N; Blum N; Schifferings C
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1249-1253. PubMed ID: 34542649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Digital health applications: statutory introduction of patient-centred digital innovations into healthcare].
    Ludewig G; Klose C; Hunze L; Matenaar S
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1198-1206. PubMed ID: 34529096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Digital health applications (DiGA): assessment of reimbursability by means of the "DiGA Fast Track" procedure at the Federal Institute for Drugs and Medical Devices (BfArM)].
    Lauer W; Löbker W; Höfgen B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1232-1240. PubMed ID: 34529095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Evidence of positive care effects by digital health apps-methodological challenges and approaches].
    König IR; Mittermaier M; Sina C; Raspe M; Stais P; Gamstätter T; Stachwitz P; Wolfrum S; Richter JG; Möckel M;
    Inn Med (Heidelb); 2022 Dec; 63(12):1298-1306. PubMed ID: 36279007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Digital health applications (DiGA) in the area of tension between progress and criticism : Discussion paper from the "Digital health" specialist group of the German Informatics Society].
    Schlieter H; Kählig M; Hickmann E; Fürstenau D; Sunyaev A; Richter P; Breitschwerdt R; Thielscher C; Gersch M; Maaß W; Reuter-Oppermann M; Wiese L
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Jan; 67(1):107-114. PubMed ID: 38086924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Market access and value-based pricing of digital health applications in Germany.
    Gensorowsky D; Witte J; Batram M; Greiner W
    Cost Eff Resour Alloc; 2022 Jun; 20(1):25. PubMed ID: 35698135
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Digital health applications from a government-regulated directory of reimbursable health apps in Germany-a systematic review for evidence and bias.
    Dittrich F; Mielitz A; Pustozerov E; Lawin D; von Jan U; Albrecht UV
    Mhealth; 2023; 9():35. PubMed ID: 38023782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence requirements of permanently listed digital health applications (DiGA) and their implementation in the German DiGA directory: an analysis.
    Mäder M; Timpel P; Schönfelder T; Militzer-Horstmann C; Scheibe S; Heinrich R; Häckl D
    BMC Health Serv Res; 2023 Apr; 23(1):369. PubMed ID: 37069592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Support for innovation at the BfArM-experiences from the consultations on digital health applications (DiGA)].
    Löbker W; Böhmer AC; Höfgen B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1241-1248. PubMed ID: 34519834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The German Fast Track Toward Reimbursement of Digital Health Applications: Opportunities and Challenges for Manufacturers, Healthcare Providers, and People With Diabetes.
    Schliess F; Affini Dicenzo T; Gaus N; Bourez JM; Stegbauer C; Szecsenyi J; Jacobsen M; Müller-Wieland D; Kulzer B; Heinemann L
    J Diabetes Sci Technol; 2024 Mar; 18(2):470-476. PubMed ID: 36059268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Digital health applications (DiGA) in medical and psychotherapeutic care. Opportunities and challenges from the perspective of the healthcare providers].
    Gerlinger G; Mangiapane N; Sander J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1213-1219. PubMed ID: 34550412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Digital respiratory sleep medicine-part I: diagnosis].
    Schöbel C; Woehrle H
    Somnologie (Berl); 2020; 24(3):138-144. PubMed ID: 32904614
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.